However, treatment of mice from day 1 postinfection with the highly efficacious small‐molecule NLRP3 inhibitor MCC950 rendered mice more susceptible to infection, raising safety concerns regarding potent ablation of NLRP3 responses as a therapeutic strategy. This evidence concerns the gene NLRP3 and infection.